Cellular reprogramming: recent advances in modeling neurological diseases
- PMID: 22072658
- PMCID: PMC3236609
- DOI: 10.1523/JNEUROSCI.4218-11.2011
Cellular reprogramming: recent advances in modeling neurological diseases
Abstract
The remarkable advances in cellular reprogramming have made it possible to generate a renewable source of human neurons from fibroblasts obtained from skin samples of neonates and adults. As a result, we can now investigate the etiology of neurological diseases at the cellular level using neuronal populations derived from patients, which harbor the same genetic mutations thought to be relevant to the risk for pathology. Therapeutic implications include the ability to establish new humanized disease models for understanding mechanisms, conduct high-throughput screening for novel biogenic compounds to reverse or prevent the disease phenotype, identify and engineer genetic rescue of causal mutations, and develop patient-specific cellular replacement strategies. Although this field offers enormous potential for understanding and treating neurological disease, there are still many issues that must be addressed before we can fully exploit this technology. Here we summarize several recent studies presented at a symposium at the 2011 annual meeting of the Society for Neuroscience, which highlight innovative approaches to cellular reprogramming and how this revolutionary technique is being refined to model neurodevelopmental and neurodegenerative diseases, such as autism spectrum disorders, schizophrenia, familial dysautonomia, and Alzheimer's disease.
References
-
- Abazyan B, Nomura J, Kannan G, Ishizuka K, Tamashiro KL, Nucifora F, Pogorelov V, Ladenheim B, Yang C, Krasnova IN, Cadet JL, Pardo C, Mori S, Kamiya A, Vogel MW, Sawa A, Ross CA, Pletnikov MV. Prenatal interaction of mutant DISC1 and immune activation produces adult psychopathology. Biol Psychiatry. 2010;68:1172–1181. - PMC - PubMed
-
- Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet. 1999;23:185–188. - PubMed
-
- Anderson SL, Qiu J, Rubin BY. EGCG corrects aberrant splicing of IKAP mRNA in cells from patients with familial dysautonomia. Biochem Biophys Res Commun. 2003a;310:627–633. - PubMed
-
- Anderson SL, Qiu J, Rubin BY. Tocotrienols induce IKBKAP expression: a possible therapy for familial dysautonomia. Biochem Biophys Res Commun. 2003b;306:303–309. - PubMed
Publication types
MeSH terms
Grants and funding
- RC4 NS073015/NS/NINDS NIH HHS/United States
- R01 NS072381/NS/NINDS NIH HHS/United States
- NS073015/NS/NINDS NIH HHS/United States
- R01 NS052671/NS/NINDS NIH HHS/United States
- NS048271/NS/NINDS NIH HHS/United States
- MH092931/MH/NIMH NIH HHS/United States
- NS066390/NS/NINDS NIH HHS/United States
- R01 MH092931/MH/NIMH NIH HHS/United States
- R01 NS048271/NS/NINDS NIH HHS/United States
- R01 NS047344/NS/NINDS NIH HHS/United States
- HD069184/HD/NICHD NIH HHS/United States
- DPOD006395/PHS HHS/United States
- NS072381/NS/NINDS NIH HHS/United States
- R01 HD069184/HD/NICHD NIH HHS/United States
- NS052671/NS/NINDS NIH HHS/United States
- R01 NS066390/NS/NINDS NIH HHS/United States
- R33 MH087874/MH/NIMH NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials